Penumbra, Inc.
Financials
Valuation Metrics
Penumbra, Inc.'s Market Cap is $12.49B. At end of 2025 it was $12.18B. Ranked #797 of 3,121 in US market (top 26%), #547 of 1,658 on NYSE (top 33%), #50 of 205 in Health Care Equipment & Services (top 24%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $12.49B | US#797/3,121 Sec#50/205 |
| Revenue | $1.50B | US#1,621/3,121 Sec#98/205 |
| Net Income | $161M | US#1,402/3,121 Sec#69/205 |
| Total Assets | $1.97B | US#2,097/3,121 Sec#106/205 |
| Net Assets | $1.53B | US#1,459/3,121 Sec#74/205 |
| Employees | 4,700 | US#1,259/3,121 Sec#90/205 |
| Value | ||
| P/E | 77.79x | US#2,049/3,121 Sec#106/205 |
| P/B | 8.16x | US#2,538/3,121 Sec#162/205 |
| PEG | 8.92x | US#1,239/3,121 Sec#67/205 |
| P/S | 8.30x | US#2,622/3,121 Sec#176/205 |
| EV/EBITDA | 56.24x | US#2,380/3,121 Sec#129/205 |
| FCF Yield | 1.73% | US#2,077/3,121 Sec#124/205 |
| Profitability | ||
| ROE | 10.49% | US#1,317/3,121 Sec#65/205 |
| ROA | 8.13% | US#643/3,121 Sec#37/205 |
| Op. Margin | 12.45% | US#1,400/3,121 Sec#57/205 |
| Revenue Growth | 17.55% | US#789/3,121 Sec#51/205 |
| Earnings Growth | 8.72% | US#1,116/3,121 Sec#62/205 |
| Financial Health | ||
| Debt Ratio | 29.00% | US#321/3,121 Sec#32/205 |
| Total Debt | $213M | US#2,232/3,121 Sec#121/205 |
| FCF | $216M | US#1,345/3,121 Sec#78/205 |
| Cash | $205M | US#1,715/3,121 Sec#100/205 |
| Current Ratio | 5.75x | US#408/3,121 Sec#30/205 |
| Net Debt/EBITDA | 0.03x | US#596/3,121 Sec#44/205 |
| Performance | ||
| 1Y Return | 23.23% | US#1,045/3,121 Sec#81/205 |
| 1M Return | -2.82% | US#1,181/3,121 Sec#104/205 |
| From 52W High | -12.36% | US#886/3,121 Sec#73/205 |
| 1Y MDD | -13.72% | US#234/3,121 Sec#5/205 |
| Trading | ||
| Volume | 531,881 shares | US#2,244/3,121 Sec#158/205 |
| Trading Value | $169M | US#708/3,121 Sec#61/205 |
| Per Share | ||
| EPS | $4.08 | US#833/3,121 Sec#45/205 |
| BPS | $38.92 | US#640/3,121 Sec#43/205 |
Company Info
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.